Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Kathy has over 20 years of industrial experience gained at SmithKline Beecham and AstraZeneca. Kathy has worked on the development and implementation of new screening approaches including FMAT and recently label-free based screening. Kathy led the implementation of label-free cell-based screening within AstraZeneca.


BSc in Biochemistry, University of Bath.


Kathy is a key opinion leader in the application of label free screening, presenting at global screening conferences and published articles on label-free in peer reviewed journals.